Gain Therapeutics (GANX) Accounts Payables (2020 - 2026)

Gain Therapeutics has reported Accounts Payables for 7 years, with the latest figure at $1.2 million in Q2 2026.

• On a quarterly basis, Accounts Payables fell 55.02% year-over-year to $1.2 million in Q2 2026; TTM through Jun 2026 was $1.2 million, a 55.02% decrease from a year earlier, with the FY2025 full-year figure at $825027.0, down 12.81% from the prior year.
• Accounts Payables was $1.2 million for Q2 2026 at Gain Therapeutics, down from $1.5 million in the prior quarter.
• The five-year high for Accounts Payables was $2.7 million in Q2 2025, with the low at $825027.0 in Q4 2025.
• Average Accounts Payables over 5 years is $1.5 million, with a median of $1.4 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Accounts Payables soared 190.13% in 2022, then slumped 55.02% in 2026.
• Over 5 years, Accounts Payables stood at $1.6 million in 2022, then decreased by 18.89% to $1.3 million in 2023, then fell by 28.26% to $946259.0 in 2024, then retreated by 12.81% to $825027.0 in 2025, then jumped by 47.92% to $1.2 million in 2026.
• The last three Accounts Payables figures came in at $1.2 million (Q2 2026), $1.5 million (Q1 2026), and $825027.0 (Q4 2025), per Business Quant data.